SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback